文献速递头颈与中枢神经肿瘤

术后放疗联合或不联合西妥昔单抗治疗中危头颈癌

Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
PubMed 文献 · J Clin Oncol · 2025-01-22

研究纳入完全切除、具有术后放疗指征的中危头颈鳞癌患者,随机比较调强放疗联合每周西妥昔单抗与单纯放疗。联合组无病生存显著改善,但总生存未显著改善,且仅在HPV阴性亚组中观察到获益。联合组急性3-4级毒性显著增加,远期≥3级毒性无显著差异。

要点

  • 联合西妥昔单抗显著改善无病生存(HR 0.75,5年无病生存71.7% vs 63.6%),总生存未显著改善(HR 0.81,5年总生存76.5% vs 68.7%)。
  • 获益仅在HPV阴性亚组中观察到,该亚组占试验患者的80.2%。
  • 联合组3-4级急性毒性显著高于单纯放疗组(70.3% vs 39.7%),远期≥3级毒性无显著差异(33.2% vs 29.0%)。

核心结论

  • 对于完全切除的中危头颈鳞癌,放疗联合西妥昔单抗较单纯放疗显著改善无病生存,但未显著改善总生存,且未增加远期毒性。
  • 放疗联合西妥昔单抗是经过仔细选择的HPV阴性患者的合适选择。

研究设计与样本

  • 随机对照试验,2009年11月至2018年3月入组702例,其中577例随机分组且符合条件。
  • 患者为口腔、口咽或喉头颈鳞癌,完全切除后具有一项或以上需要术后放疗的危险因素。
  • 按1:1随机分配至调强放疗(60-66 Gy)联合每周西妥昔单抗组或单纯放疗组。
  • 主要假设为联合组改善随机分组且符合条件患者的总生存,预设次要计划在HPV阴性亚组中检验。
  • 无病生存和毒性为次要终点;总生存和无病生存采用分层log-rank检验,毒性采用Fisher精确检验。

主要发现

  • 大多数患者(63.6%)为口腔癌,大多数(84.6%)具有高表皮生长因子受体表达。
  • 死亡人数(184例)少于预期。
  • 中位随访7.2年,总生存未显著改善(HR 0.81;单侧P=0.0747;5年总生存76.5% vs 68.7%),无病生存显著改善(HR 0.75;单侧P=0.0168;5年无病生存71.7% vs 63.6%)。
  • 放疗联合西妥昔单抗的获益仅在HPV阴性亚组中观察到(占试验患者的80.2%)。
  • 3-4级急性毒性发生率联合组为70.3%,单纯放疗组为39.7%(双侧P<0.0001),主要为皮肤和/或黏膜反应。

临床怎么用

  • 对于完全切除的中危头颈鳞癌,放疗联合西妥昔单抗是经过仔细选择的HPV阴性患者的合适选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiotherapy (RT)/cetuximab (C) demonstrated superiority over RT alone for locally advanced squamous head and neck cancer. We tested this in completely resected, intermediate-risk cancer. METHODS: Patients had squamous cell carcinoma of the head and neck (SCCHN) of the oral cavity, oropharynx, or larynx, with one or more risk factors warranting postoperative RT. Patients were randomly assigned 1:1 to intensity-modulated RT (60-66 Gy) with once-per-week C or RT alone. The primary hypothesis was that RT + C would improve overall survival (OS) in randomly assigned/eligible patients, with a prespecified secondary plan to test this in the human papillomavirus (HPV)-negative subpopulation. Disease-free survival (DFS) and toxicity were secondary end points. OS and DFS were tested via stratified log-rank test; toxicity was compared via Fisher's exact test. RESULTS: We enrolled 702 patients from November 2009 to March 2018; 577 were randomly assigned/eligible. Most (63.6%) had oral cavity cancer and most (84.6%) had high epidermal growth factor receptor expression. There were fewer deaths (184) than expected. OS (median follow up, 7.2 years) was not significantly improved (hazard ratio [HR], 0.81; one-sided P = .0747; 5-year OS 76.5% v 68.7%), but DFS was (HR, 0.75; one-sided P = .0168; 5-year DFS 71.7% v 63.6%). Benefit of RT + C was only seen in the HPV-negative subpopulation (80.2% of patients in the trial). Grade 3-4 acute toxicity rates were 70.3% (RT + C) versus 39.7% (RT; two-sided P < .0001), mostly skin and/or mucosal effects. Late grade ≥3 toxicity rate was 33.2% (RT + C) versus 29.0% (RT; two-sided P = .3101). There were no grade 5 toxicities in either arm. CONCLUSION: RT + C significantly improved DFS, but not OS, with no increase in long-term toxicity, compared with RT alone for resected, intermediate-risk SCCHN. RT + C is an appropriate option for carefully selected patients with HPV-negative disease.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Machtay M, Torres-Saavedra PA, Thorstad W, et al. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. J Clin Oncol. 2025. PMID: 39841939. doi:10.1200/JCO-24-01829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。